Halozyme Therapeutics (HALO) 14.63 $HALO
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 20, 7:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HALO: 14.63 (-1.43), VCYT: 7.31 (-0.99), VTL: 24.86 (-2.51), ZSAN: 9.97 (-1.70), FCCY: 10.63 (-1.12)
64.6% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Thu Mar 19, 9:20AM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 64.62% as of today's recent price of $16.38.
HALO: 14.63 (-1.43)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 36.03 (+0.40), ZIOP: 13.89 (-0.11), HALO: 14.63 (-1.43), DRNA: 24.81 (-1.69), AKAM: 72.87 (+0.12), JUNO: 61.53 (+1.85), LBIO: 13.59 (-0.90), FIVE: 31.86 (+0.49), ROST: 107.46 (+0.72)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 14.63 (-1.43), TROV: 7.04 (-0.35), ILMN: 196.02 (-3.79)
Halozyme Therapeutics Has Returned 54.9% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Wed Mar 11, 4:53PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 54.87% as of today's recent price of $15.41.
HALO: 14.63 (-1.43)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 34.45 (-0.54), HALO: 14.63 (-1.43), GILD: 102.29 (+0.85), JUNO: 61.53 (+1.85), ARNA: 4.80 (-0.21)
Clinical trial planned to assess Halozyme's Enhanze in subcutaneous version of cancer drug
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 12:23PM CDT
JNJ: 102.40 (+0.71), HALO: 14.63 (-1.43)
Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders
at The Street - Tue Mar 10, 12:16PM CDT
Stocks with insider trader activity include GCAP, HALO and ALIM
HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), GCAP: 9.75 (+0.08)
Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
PR Newswire - Tue Mar 10, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE(TM) technology. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab is being developed under a collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
HALO: 14.63 (-1.43)
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 102.40 (+0.71), HALO: 14.63 (-1.43), CBM: 36.69 (+1.04), BAX: 68.18 (+0.20)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 14.63 (-1.43)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 7:00PM CST
HALO: 14.63 (-1.43)
Halozyme Therapeutics reports 4Q loss
Automated Insights - Mon Mar 02, 5:27PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $5.3 million in its fourth quarter.
HALO: 14.63 (-1.43)
Halozyme Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:20PM CST
HALO: 14.63 (-1.43)
Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5.3 million, or $0.04 per share. This compares to revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share, for the fourth quarter of 2013. Financial highlights for the full year 2014 include revenues of $75.3 million and a net loss of $68.4 million, or $0.56 per share. This compares to revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share, in the prior year.
HALO: 14.63 (-1.43)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.24 (+0.06), GWRE: 53.65 (+0.84), CODI: 16.94 (+0.27), MDR: 3.29 (+0.01), HTGC: 13.98 (+0.33), NBR: 13.15 (+0.36), NTRI: 20.56 (+0.45), XON: 46.11 (-1.26), STKL: 11.01 (+0.50), OPWR: 10.65 (+0.14), CZR: 9.44 (unch), PANW: 144.08 (-2.11), INN: 14.23 (+0.30), CMLS: 2.68 (+0.25), MTDR: 20.17 (+0.01), ARNA: 4.80 (-0.21), MCEP: 5.43 (+0.14), SLXP: 172.80 (+0.26), BALT: 1.38 (+0.14), MYL: 63.06 (-0.88), SN: 11.80 (+0.08), EPIQ: 18.31 (+0.04), CHUY: 22.74 (+0.18), DTSI: 34.06 (-0.15), PRAA: 54.72 (+1.16), HALO: 14.63 (-1.43), CIM: 3.23 (+0.03), CKEC: 34.55 (+0.78)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Shares of HALO Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 18, 9:09AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 53.07% as of today's recent price of $15.23.
HALO: 14.63 (-1.43)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 14.63 (-1.43), IDRA: 4.18 (-0.25), HSKA: 24.80 (-0.32), KITE: 71.89 (-1.62), GILD: 102.29 (+0.85)
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 20, 7:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HALO: 14.63 (-1.43), VCYT: 7.31 (-0.99), VTL: 24.86 (-2.51), ZSAN: 9.97 (-1.70), FCCY: 10.63 (-1.12)
64.6% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Thu Mar 19, 9:20AM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 64.62% as of today's recent price of $16.38.
HALO: 14.63 (-1.43)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 36.03 (+0.40), ZIOP: 13.89 (-0.11), HALO: 14.63 (-1.43), DRNA: 24.81 (-1.69), AKAM: 72.87 (+0.12), JUNO: 61.53 (+1.85), LBIO: 13.59 (-0.90), FIVE: 31.86 (+0.49), ROST: 107.46 (+0.72)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 14.63 (-1.43), TROV: 7.04 (-0.35), ILMN: 196.02 (-3.79)
Halozyme Therapeutics Has Returned 54.9% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Wed Mar 11, 4:53PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 months, Halozyme Therapeutics has returned 54.87% as of today's recent price of $15.41.
HALO: 14.63 (-1.43)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 34.45 (-0.54), HALO: 14.63 (-1.43), GILD: 102.29 (+0.85), JUNO: 61.53 (+1.85), ARNA: 4.80 (-0.21)
Clinical trial planned to assess Halozyme's Enhanze in subcutaneous version of cancer drug
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 12:23PM CDT
JNJ: 102.40 (+0.71), HALO: 14.63 (-1.43)
Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders
at The Street - Tue Mar 10, 12:16PM CDT
Stocks with insider trader activity include GCAP, HALO and ALIM
HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), GCAP: 9.75 (+0.08)
Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration
PR Newswire - Tue Mar 10, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE(TM) technology. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab is being developed under a collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
HALO: 14.63 (-1.43)
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 102.40 (+0.71), HALO: 14.63 (-1.43), CBM: 36.69 (+1.04), BAX: 68.18 (+0.20)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 14.63 (-1.43)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 7:00PM CST
HALO: 14.63 (-1.43)
Halozyme Therapeutics reports 4Q loss
Automated Insights - Mon Mar 02, 5:27PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $5.3 million in its fourth quarter.
HALO: 14.63 (-1.43)
Halozyme Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:20PM CST
HALO: 14.63 (-1.43)
Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5.3 million, or $0.04 per share. This compares to revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share, for the fourth quarter of 2013. Financial highlights for the full year 2014 include revenues of $75.3 million and a net loss of $68.4 million, or $0.56 per share. This compares to revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share, in the prior year.
HALO: 14.63 (-1.43)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.24 (+0.06), GWRE: 53.65 (+0.84), CODI: 16.94 (+0.27), MDR: 3.29 (+0.01), HTGC: 13.98 (+0.33), NBR: 13.15 (+0.36), NTRI: 20.56 (+0.45), XON: 46.11 (-1.26), STKL: 11.01 (+0.50), OPWR: 10.65 (+0.14), CZR: 9.44 (unch), PANW: 144.08 (-2.11), INN: 14.23 (+0.30), CMLS: 2.68 (+0.25), MTDR: 20.17 (+0.01), ARNA: 4.80 (-0.21), MCEP: 5.43 (+0.14), SLXP: 172.80 (+0.26), BALT: 1.38 (+0.14), MYL: 63.06 (-0.88), SN: 11.80 (+0.08), EPIQ: 18.31 (+0.04), CHUY: 22.74 (+0.18), DTSI: 34.06 (-0.15), PRAA: 54.72 (+1.16), HALO: 14.63 (-1.43), CIM: 3.23 (+0.03), CKEC: 34.55 (+0.78)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Shares of HALO Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 18, 9:09AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 53.07% as of today's recent price of $15.23.
HALO: 14.63 (-1.43)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 14.63 (-1.43), IDRA: 4.18 (-0.25), HSKA: 24.80 (-0.32), KITE: 71.89 (-1.62), GILD: 102.29 (+0.85)
